The present invention relates to a plasticizer composition, a resin composition, and preparation methods therefor, and can provide: a plasticizer capable of improving physical properties such as plasticizing efficiency, migration, tensile strength, elongation, stress migration and light resistance, which are required in sheet formulation, when used as a plasticizer of a resin composition by improving inferior physical properties generated because of structural limitations; and a resin composition containing the same.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

A process of separating carboxylic acids comprising two steps. The first step is to provide an aqueous solution comprising (i) one or more mono-carboxylic acids, (ii) one or more di-carboxylic acids, and (iii) one or more tri-carboxylic acids. The second step is to pass the aqueous solution through a collection of resin particles, where the resin particles comprise covalently bound quaternary ammonium groups, and wherein the collection of resin particles has uniformity coefficient of 1.5 or less.

A process of separating carboxylic acids comprising two steps. The first step is to provide an aqueous solution comprising (i) one or more mono-carboxylic acids, (ii) one or more di-carboxylic acids, and (iii) one or more tri-carboxylic acids. The second step is to pass the aqueous solution through a collection of resin particles, where the resin particles comprise covalently bound quaternary ammonium groups, and wherein the collection of resin particles has uniformity coefficient of 1.5 or less.

The present disclosure relates to free base and salt crystals of 2-(4-acetylbenzyl)-3-((4-fluorophenyl)amino)-5,7,7-trimethyl-7,8-dihydro-2H-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, composition comprising the same and the method of making and using such free base and salt crystals.

The present invention relates to salts of a PI3Kdelta inhibitor (referred to as Compound A hereinafter), preferably fumarate, and the crystalline forms thereof. The present invention also relates to the process of preparation and uses of the salts and crystalline forms of Compound A.

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described. ##STR00001##

A highly pure form of ferric citrate and an industrially viable and advantageous process for its preparation are described. ##STR00001##

The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.